X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA FRESENIUS KABI ONCO. AJANTA PHARMA/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 28.3 22.1 128.1% View Chart
P/BV x 11.7 3.1 375.3% View Chart
Dividend Yield % 0.5 0.0 -  

Financials

 AJANTA PHARMA   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-16
FRESENIUS KABI ONCO.
Mar-13
AJANTA PHARMA/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs1,720176 977.3%   
Low Rs1,10379 1,405.1%   
Sales per share (Unadj.) Rs194.637.7 516.4%  
Earnings per share (Unadj.) Rs45.25.1 887.8%  
Cash flow per share (Unadj.) Rs50.36.7 748.1%  
Dividends per share (Unadj.) Rs8.000-  
Dividend yield (eoy) %0.60-  
Book value per share (Unadj.) Rs132.042.5 310.3%  
Shares outstanding (eoy) m88.77158.23 56.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.33.4 214.8%   
Avg P/E ratio x31.225.0 124.9%  
P/CF ratio (eoy) x28.118.9 148.3%  
Price / Book Value ratio x10.73.0 357.4%  
Dividend payout %17.70-   
Avg Mkt Cap Rs m125,29920,135 622.3%   
No. of employees `000NA1.2 0.0%   
Total wages/salary Rs m2,570703 365.5%   
Avg. sales/employee Rs ThNM5,176.2-  
Avg. wages/employee Rs ThNM610.4-  
Avg. net profit/employee Rs ThNM699.6-  
INCOME DATA
Net Sales Rs m17,2755,963 289.7%  
Other income Rs m16618 923.9%   
Total revenues Rs m17,4425,981 291.6%   
Gross profit Rs m5,8071,430 406.1%  
Depreciation Rs m451258 174.7%   
Interest Rs m49-26 -188.1%   
Profit before tax Rs m5,4741,216 450.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m1,460342 426.6%   
Profit after tax Rs m4,014806 498.1%  
Gross profit margin %33.624.0 140.2%  
Effective tax rate %26.728.1 94.8%   
Net profit margin %23.213.5 171.9%  
BALANCE SHEET DATA
Current assets Rs m7,6395,102 149.7%   
Current liabilities Rs m2,7152,385 113.8%   
Net working cap to sales %28.545.6 62.6%  
Current ratio x2.82.1 131.6%  
Inventory Days Days43150 28.8%  
Debtors Days Days79113 69.4%  
Net fixed assets Rs m6,9145,148 134.3%   
Share capital Rs m177158 111.8%   
"Free" reserves Rs m11,4426,556 174.5%   
Net worth Rs m11,7216,732 174.1%   
Long term debt Rs m149952 15.6%   
Total assets Rs m14,81410,388 142.6%  
Interest coverage x112.9-45.8 -246.7%   
Debt to equity ratio x00.1 9.0%  
Sales to assets ratio x1.20.6 203.1%   
Return on assets %27.47.5 365.3%  
Return on equity %34.212.0 286.1%  
Return on capital %46.514.6 318.6%  
Exports to sales %55.174.5 74.1%   
Imports to sales %6.024.8 24.2%   
Exports (fob) Rs m9,5274,441 214.5%   
Imports (cif) Rs m1,0381,477 70.2%   
Fx inflow Rs m10,4225,298 196.7%   
Fx outflow Rs m1,6781,772 94.7%   
Net fx Rs m8,7443,525 248.0%   
CASH FLOW
From Operations Rs m3,2641,274 256.2%  
From Investments Rs m-2,093-1,204 173.8%  
From Financial Activity Rs m-1,186-196 604.6%  
Net Cashflow Rs m-15-126 11.7%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 9.6 79.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 42,599 49.2%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  DR. REDDYS LAB  GSK PHARMA  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Of Global Markets Hitting Record Highs and Top Stocks in Action During the Week(RoundUp)

Global stock markets ended the week on a positive note. Benchmark indices in US grew by 1% during the week. The Down Jones Industrial Average topped the 26,000.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Jan 19, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS